N/A
Completed N=72
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol
Source: ClinicalTrials.gov NCT04912089 ↗Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcomePrimary: Change in Cognitive Performance — 4.92; 8.18; .27 score on a scale
Summary
The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to a high dose, low dose, or assessment only condition. Participants will be compared on cognitive performance and brain response during cognitive tasks from baseline to post-treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Cognitive Performance |
4.92; 8.18; .27 | — |
| SECONDARY Change in Reading Span Blood Oxygen Level Dependent (BOLD) Response |
-2.90; -2.16; 2.46 | — |
| SECONDARY Change in Emotional Working Memory Blood Oxygen Level Dependent (BOLD) Response |
.21; .58; -1.56 | — |
| SECONDARY Change in Neuropsychological Performance |
4.35; 7.94; 1.37 | — |
| SECONDARY Anxiety Symptoms |
-1.21; -4.28; -1.14 | — |
| SECONDARY Symptoms of Depression |
-2.46; -1.56; -1.48 | — |
| SECONDARY PTSD Symptoms |
-6.46; -4.39; -7.91 | — |
| SECONDARY Change Repetitive Negative Thinking (RNT) |
-.09; -.12; .01 | — |
| SECONDARY Self-reported Attention Attention |
-.04; 1.89; 1.05 | — |
| SECONDARY Emotion Regulation |
-1.04; -1.06; .59 | — |
| SECONDARY Disability |
-1.66; -1.42; -.32 | — |
| SECONDARY Suicide Cognitions |
-2.79; -5.44; -5.18 | — |
| SECONDARY Alcohol Use |
.17; -.17; .14 | — |
| SECONDARY Drug Abuse |
.00; .11; -.09 | — |
| SECONDARY Insomnia |
-.21; -3.06; -2.09 | — |
| SECONDARY Change in Mood and Emotions: Negative Affect |
-3.38; -5.06; -.38 | — |
| SECONDARY Change in Mood and Emotion: Positive Affect |
1.25; 2.55; .32 | — |
Eligibility Criteria
Inclusion Criteria
- age 21-55
- fluent in English
- diagnosis of mood, anxiety, or traumatic stress disorder
- clinically elevated repetitive negative thinking
- outpatient status
- 6-week stability if taking selective serotonin reuptake inhibitor (SSRI) medications
Exclusion Criteria
- past year diagnosis of severe alcohol or moderate or greater substance use disorder
- lifetime history of psychotic or bipolar I disorder
- acute suicidality necessitating immediate clinical intervention
- neurodegenerative or neurodevelopmental disorders
- history of moderate or severe traumatic brain injury or other known neurological condition
- sensory deficits that would preclude completing tasks
- conditions unsafe for completing MRI scanning (e.g., metal in body)
- currently receiving psychosocial treatment
- currently receiving psychiatric pharmacotherapy, except SSRIs
Data sourced from ClinicalTrials.gov (NCT04912089). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.